Skip to main content
Premium Trial:

Request an Annual Quote

Codexis, Alphazyme Ink Comarketing, Production Agreement for Enzymes

NEW YORK – Codexis and Alphazyme announced on Monday a collaboration agreement for the production and comarketing of enzymes for life science and diagnostic applications.

Under the terms of the agreement, Alphazyme will be the exclusive manufacturer of three Codexis-developed enzymes: a high-fidelity DNA polymerase, an evolved T7 RNA polymerase for manufacturing of RNA therapeutics and vaccines, and a reverse transcriptase. Alphazyme will also gain comarketing rights to certain Codexis enzymes. The firms will promote and sell these enzymes in the life science and diagnostic markets, and they plan to add more products over time.

Financial and other details of the agreement were not disclosed.

"We are delighted to partner with the experienced team at Alphazyme to launch our high fidelity DNA polymerase into the NGS market, alongside the rapid development of a reverse transcriptase for viral diagnostics and the commercialization of our evolved T7 RNA polymerase for efficient mRNA production," Codexis President and CEO John Nicols said in a statement. "In partnership with Alphazyme, Codexis can play a key role in providing solutions to critical molecular biology challenges across a number of applied markets. These challenges have never been more apparent, or in need of resolution, than they are today."

Redwood City, California-based Codexis engineers proteins using a proprietary CodeEvolver platform for use in several industries, including pharmaceutical and chemical manufacturing and industrial enzyme production.

In December 2019, Codexis licensed its EvoT4 DNA ligase enzyme to Roche for use in next-generation sequencing library preparation kits.

In May, Jupiter, Florida-based Alphazyme licensed Dyadic International's C1 Gene expression platform for enzyme production.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.